Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Treatment With a Biologic: A Case Report

Perm J. 2017:21:16-060. doi: 10.7812/TPP/16-060.

Abstract

Introduction: One of the most dangerous dermatologic emergencies is Stevens-Johnson Syndrome (SJS)/toxic epidermal necrolysis (TEN). Although a rare disease, it can often lead to significant mortality.

Case presentation: In this case report, we present a 77-year-old man who developed a sloughing rash that was secondary to a nonsteroidal anti-inflammatory drug. In addition to the recommended supportive care, the patient was treated with etanercept, a new, less commonly used intervention.

Discussion: We provide a brief review of SJS/TEN. Nonsteroidal anti-inflammatory drugs are a rare cause of SJS/TEN, and additionally, the use of biologics is a novel treatment modality for SJS/TEN.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Biological Products / therapeutic use*
  • Etanercept / therapeutic use*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Stevens-Johnson Syndrome / drug therapy*

Substances

  • Biological Products
  • Immunosuppressive Agents
  • Etanercept